416 related articles for article (PubMed ID: 21507583)
1. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
Swisher SG; Winter KA; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1967-72. PubMed ID: 21507583
[TBL] [Abstract][Full Text] [Related]
2. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation.
Swisher SG; Moughan J; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
J Thorac Oncol; 2017 Feb; 12(2):368-374. PubMed ID: 27729298
[TBL] [Abstract][Full Text] [Related]
3. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.
Suntharalingam M; Winter K; Ilson D; Dicker AP; Kachnic L; Konski A; Chakravarthy AB; Anker CJ; Thakrar H; Horiba N; Dubey A; Greenberger JS; Raben A; Giguere J; Roof K; Videtic G; Pollock J; Safran H; Crane CH
JAMA Oncol; 2017 Nov; 3(11):1520-1528. PubMed ID: 28687830
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL
Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
[TBL] [Abstract][Full Text] [Related]
8. Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.
Schneider BJ; Lee JS; Hayman JA; Chang AC; Orringer MB; Pickens A; Pan CC; Merajver SD; Urba SG
Invest New Drugs; 2013 Apr; 31(2):435-42. PubMed ID: 22847786
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer.
Swisher SG; Ajani JA; Komaki R; Nesbitt JC; Correa AM; Cox JD; Lahoti S; Martin F; Putnam JB; Smythe WR; Vaporciyan AA; Walsh GL; Roth JA
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):120-7. PubMed ID: 12909224
[TBL] [Abstract][Full Text] [Related]
11. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
Jeene PM; Versteijne E; van Berge Henegouwen MI; Bergmann JJ; Geijsen ED; Muller K; van Laarhoven HW; Hulshof MC
Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27766725
[TBL] [Abstract][Full Text] [Related]
12. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone.
Chen Y; Lu Y; Wang Y; Yang H; Xia Y; Chen M; Song H; Li T; Li D; Wang J; Li S; Wang J
Dis Esophagus; 2014; 27(2):134-40. PubMed ID: 23088212
[TBL] [Abstract][Full Text] [Related]
13. Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report.
Goldberg M; Farma J; Lampert C; Colarusso P; Coia L; Frucht H; Goosenberg E; Beard M; Weiner LM
J Thorac Cardiovasc Surg; 2003 Oct; 126(4):1168-73. PubMed ID: 14566264
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
[TBL] [Abstract][Full Text] [Related]
15. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
[TBL] [Abstract][Full Text] [Related]
16. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
Choong NW; Mauer AM; Haraf DC; Ferguson MK; Sandler AB; Kesler KA; Fishkin PA; Ansari RH; Wade J; Krauss SA; Sciortino DF; Posner MC; Kocherginsky M; Hoffman PC; Szeto L; Vokes EE
Med Oncol; 2011 Dec; 28 Suppl 1():S152-61. PubMed ID: 20730572
[TBL] [Abstract][Full Text] [Related]
18. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Higuchi K; Komori S; Tanabe S; Katada C; Azuma M; Ishiyama H; Sasaki T; Ishido K; Katada N; Hayakawa K; Koizumi W;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):872-9. PubMed ID: 24867539
[TBL] [Abstract][Full Text] [Related]
19. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial.
Pöttgen C; Gkika E; Stahl M; Abu Jawad J; Gauler T; Kasper S; Trarbach T; Herrmann K; Lehmann N; Jöckel KH; Lax H; Stuschke M
Radiat Oncol; 2021 Mar; 16(1):59. PubMed ID: 33757534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
